

**Supplementary Table S2. Matched pre-pandemic reference registry cohort from 2020 (N=2182)**

<b>Gender, N (%)</b>	
Female	1724 (79.0)
Male	458 (21.0)
<b>Age at MS onset [years], median (range)</b>	30.0 (24.0–37.3)
<b>Disease duration [years], median (range)</b>	13.3 (6.8–21.3)
<b>Time to diagnosis [years], median (range)</b>	0.3 (0.0–2.2)
<b>MS disease course, N (%)</b>	
RRMS	1773 (81.3)
SPMS	409 (18.7)
<b>Disability level (EDSS), N (%)</b>	
Mild (0–2.5)	1168 (53.5)
Moderate (3.0–5.5)	730 (33.5)
Severe (≥6.0)	284 (13.0)
<b>DMD treatment, N (%)</b>	
High-efficacy DMD	659 (30.2)
Mild-moderate-efficacy DMD	960 (44.0)
DMD-untreated	563 (25.8)

DMD – disease-modifying drug

EDSS – expanded disability status scale

MS – multiple sclerosis

N – number of patients

RRMS – relapsing remitting MS

SPMS – secondary progressive MS